Thread by @DopeinkInvest

Prof Sharon Peacock Cambridge Uni, her work sequencing variants may be required for at least 10 yrs

bbc.co.uk/news/uk-560199…

#Novacyt #ALNOV #NCYT

Prof Sharon Peacock will be speaking at Novacyt's NovaTalk on 26th Feb

https://twitter.com/gggg2120/status/1359583252080701456?s=19

#Novacyt #ALNOV #NCYT

https://twitter.com/PrimerdesignLtd/status/1357658991103516674?s=19

(April) Novacyt Partners With AstraZeneca, GSK, University Of Cambridge To Increase COVID-19 Testing

#Novacyt #ALNOV #NCYT

"5-10% of positive tests are selected randomly to be sent on for further genome analysis but the consortium says that it has an aim to genetically screen every positive coronavirus test"

Covid-19 Genomics UK Consortium

#Novacyt #ALNOV #NCYT

https://twitter.com/CovidGenomicsUK/status/1357337269166764036?s=19

https://twitter.com/PrimerdesignLtd/status/1359820232680964097?s=19

https://twitter.com/DopeinkInvest/status/1359666767988199425?s=19

“primary challenge for COVID-19 diagnostics companies is ensuring their products continue to accurately test for the virus, regardless of the variant, and to innovate at the challenging pace required to remain clinically relevant,” Graham Mullis, Novacyt
bioworld.com/articles/50347…

"from what we know today, both the antigen RDTs & the majority of the molecular diagnostic tools are okay,” Carmona said.

“There are some PCR-targeted solutions just to detect those mutations, but those would be mostly confined for research and monitoring emerging variants.”

#Novacyt
"recently launched a PCR genotyping assay portfolio to detect COVID-19 variants. Based on the analysis of single nucleotide polymorphisms (SNPs), the SNPsig portfolio is designed to run on central laboratory systems on the company’s q16 and q32 rapid PCR systems"

"first three SNPsig assays enable the identification of the original strain of the virus, the U.K. (B.1.1.7), South Africa (B.1.351) and Brazil (B.1.1.28) variants, as well as any new variant carrying the N501Y mutation"

#Novacyt #ALNOV #NCYT

#Novacyt’s dynamic innovation model enabled them "to keep track of new SARS-CoV-2 variants in real time as they arise and, as a result, continue to analyze our assays to ensure they remain able to detect the virus with the same high level of accuracy,” #NCYT #ALNOV

#Novacyt began the surveillance program when there were just a few hundred reported SARS-CoV-2 sequences. Now 308,000. #NCYT continues to review them each week. #ALNOV is working with a global network of virologists, tracking variants to identify mutations as they are reported